Background: Cell-free circulating DNA (cfDNA) and circulating tumor cells (CTCs) are emerging
Introduction

Material and methods
Clinical samples
cfDNA and CTCs samples obtained from 20 patients with confirmed diagnoses of gynecologic cancer were subjected to targeted sequencing using our customized cancer panel. All subjects provided informed consent to participate and all clinical specimens were collected in accordance with IRBs at Chonbuk National University Hospital. Detailed clinicopathologic information for the 20 cases are provided in Table 1 and Supplementary Table S1 . A total of 7 ml of whole peripheral blood was collected in EDTA tubes from each patient. 2 ml of blood was processed with CTC enrichment and 5 ml used for the plasma preparation. 
Sample Preparation
Plasma was isolated from 5 ml of whole blood using density gradient centrifugation in FicollPaque TM PLUS (GE Healthcare). cfDNA was extracted from isolated plasma samples using the QIAamp Circulating Nucleic Acid Kit (Qiagen) according to the manufacturer's instructions. cfDNA was extracted from 2 ml to 4 ml of plasma and quantified using Qubit 3.0 fluorometer (Invitrogen). The quality of cfDNA was measured using the 2100 Bioanalyzer (Agilent) to confirm absence of contamination with genomic DNA.
Sequencing data analysis
The human genome sequence hg19 was used as the reference. Sequence and data analysis were performed using Torrent Suite software (5.8.0). Sequencing coverage analysis was performed using coverage Analysis (5.8.0.1) plugins and VCF files were generated using the variantCaller (5.8.0.19) plugins. Annotation of the variants was obtained using the Ion Reporter (5.10.2.0) software.
To filter out potential sequencing background noise, we excluded control variants detected in cfDNA or
CTCs samples from 30 healthy individuals. Common Korean SNVs which are included in KoVariome whole genome sequence (WGS) database from 50 healthy unrelated Korean individuals 22, 23 were also excluded. We identified variants of uncertain significance (VUS) using SIFT, PolyPhen-2 and used
OncoKDM to predict the effect of genetic variants on protein function [24] [25] [26] [27] . In addition, variants were annotated using ClinVar, COSMIC, and TCGA to match them to previously reported variants. To provide further clinical implications of the annotated tumor variants, we used a precision oncology knowledge base, OncoKB 28 , which provides the guide information for FDA-approved therapies in clinical trials.
RESULTS
Patient characteristics
We performed sequencing of cfDNA and ctcDNA obtained from 20 gynecologic cancer patients to characterize the diversity of genomic variants found. The cancers grouped into five distinct types.
The most frequent type was ovarian (n=9, 45%), followed by cervical (n=4, 20%), uterine (n=3, 15%), endometrial (n=3, 15%) and vulvar cancer (n=1, 5% Figure 1A ). In BRCA2, seven missense and one nonsense mutations were identified. The Q1683* mutation leads to a truncation at BRC repeat sequences that bind to DNA meiotic recombinase 1 29 and N1100T, A3122T and K1445T were also determined to be potential pathogenic mutations. Interestingly, the V2466A germline variant was detected in all patients except patient number 10 but was determined to be a tolerated mutation ( Figure 1B ). We also observed the TP53 mutation in nine patients. The most frequently mutated genes were BRCA1, BRCA2, and TP53. In BRCA1, where three missense, two frameshift and one deletion mutations were observed. Four of these variants (K110R, Q148H, S1736I, S573fs*) were determined by in silico analyses as potential pathogenic mutations ( Figure 1A ). In BRCA2, seven missense and one nonsense mutations were identified. The Q1683* mutation leads to a truncation at BRC repeat sequences that bind to DNA meiotic recombinase 1 29 and N1100T, A3122T and K1445T were also determined to be potential pathogenic mutations. Interestingly, the V2466A germline variant was detected in all patients except patient number 10 but was determined to be a tolerated mutation ( Figure 1B ). We also observed the TP53 mutation in nine patients. 
The mutation frequencies in cfDNA and ctcDNA of gynecologic cancers
To explore the clonal heterogeneity of cfDNA and ctcDNA, sequence data from cfDNA and ctcDNA were compared. An independent mutation analysis revealed 13 somatic variants in the cfDNA sample (Supplementary Figure S1A) and 18 somatic variants in CTCs sample (Supplementary Figure   S1B ). This analysis confirmed that variants detected in cfDNA or ctcDNA, have only a 6% overlap (two out of 33 variants; Supplementary Figure S1C) indicating that the combined approach of using both methods improves accuracy of diagnoses and monitoring of tumor progression.
We detected a total of 31 genetic variants in 15 genes and 85% patients have least one variant in either cfDNA or ctcDNA. The median number of mutated genes per patients was two (range of 0-5).
The most frequently altered genes in cfDNA samples were TP53 (20%, four out of 20 cfDNA samples), PTCH1 (20%), FGFR (15%) and BRCA2 (15%). In contrast, the most frequently altered genes in ctcDNA samples were TP53 (25%, five out of 20 ctcDNA samples), BRCA1 (15%), TSC2 (15%), ERBB2
(15%) and PTCH1 (15%). The distribution of these genetic mutations in the whole population is shown in Figure 2A and 2B. 
Complementary genomic profiling of cfDNA and CTCs
Although profiling of cfDNA and CTCs liquid biopsies offer convenient analysis of genetic mutations, low levels of cfDNA and CTCs in blood limit thresholds of detection. 32 Our data found mutations in 65% and 70% of patients by analyzing cfDNA and ctcDNA, respectively. However, simultaneous analysis of both cfDNA and ctcDNA raises this number to 85% ( Figure 3A ).
Some genes in the panel were specific to either cfDNA (BRCA2, MYCN, PIK3CA, FGFR3, NOTCH1, and BTK) or ctcDNA (ERBB2, ERBB3, BAP1, TSC1, TSC2, and CDK4 ( Figure 3B ). Others were mutated in both (TP53, PTCH1, BRCA1, and FGFR1). TP53 gene variants were the most frequently found in both (45% of patients, nine out of 20 patients). Detected mutations were classified by cancer type.
Precision medicine based on genetic mutations
Genetic variants may lead to significant changes in the appearance and behavior of cancers in different individuals owing to tumor heterogeneity. Therefore, genetic variant analysis can offer potentially useful data for treatment. We detected a number of variants in cfDNA and CTCs samples of gynecologic cancers by targeted sequencing and identification of actionable variants related to drug responses using OncoKB.
For example, the germline BRCA1 p.S573fs* mutation, which produces a truncated protein leading to a loss-of-function of the BRCA1 gene, was detected in the cfDNA of ovarian cancer patient 1. Patient 5, also with ovarian cancer, has a somatic BRCA2 mutation, the detected nonsense mutation (p.Q1683*) also of which leads to loss-of-function of the BRCA2 gene. BRCA1 or BRCA2 deficient tumors are known to be more sensitive to cytotoxic agents such as platinum compounds and PARP inhibitor. 33 Therefore, rucaparib, niraparib, and olaparib as FDA-approved PARP inhibitors are recommended treatments these patients (Table 3) . 
Discussion
As panels of biomarkers obtainable from liquid biopsies, cfDNA and CTCs offer a minimally invasive practical tool for monitoring the interplay between tumor heterogeneity and clinical relevance.
Recent studies have reported that amounts of cfDNA in the blood increased in patients with cancer compared to healthy individuals and is related to tumor stage and burden in gynecologic cancers. 34, 35 Moreover, cfDNA profiles accurately reflect genomic variants found in tissue biopsies. 36 The quantity and genomic variation characteristics of CTCs have also shown intra-tumor heterogeneity and can provide comprehensive diagnostic information of a number of cancers. 37, 38 Although the advantages of cfDNA and CTCs make them promising tools, more sensitive techniques must be developed to exploit their full promise. 39, 40 In this study, we investigated the feasibility of using a targeted sequencing panel of 51 actionable genes in cancers to identify cfDNA and ctcDNA variants in patients with the five main types of gynecologic cancers. We first performed a cfDNA assay to detect somatic mutations and verify the sensitivity of the customized cancer panel for cfDNA. Our findings show that the limit of detection (LOD) was ~0.1% allelic frequencies (Multiplex 1 cfDNA Reference Standard set, data not shown). This is not sensitive enough for a reliable detection of early cancers and at least one order of magnitude gain is required in sensitivity and detection for wide-spread future use. However, for advanced, and perhaps certain types of cancers, 0.1% allelic detection can be useful enough. The most common variants found were specific to either the cfDNA or CTCs allelic pools and only two of out 33 variants were found in both. This means that either the sensitivity of current NGS-based method is too low or the two types of DNA samples, i.e., one from cfDNA and one from whole CTCs, have drastically different characteristics.
It is likely that cfDNA are selected in the blood as a result of physiological conditions and various enzymes. Therefore, although it is more difficult to filter out many CTCs, CTCs may have more complete set of tumor variants for high quality NGS data analysis. Our results confirm that analyzing cfDNA and ctcDNA together provides a far richer set of data per patient, than does examining either biomarker in isolation. Finally, in applying these technologies in a clinical setting, using NGS analysis of cfDNA and ctcDNA offers far easier access to genomic DNA suitable for diagnostic and clinical implications than traditional solid tumor analysis. Furthermore, combined solid and liquid biopsies using NGS can provide doctors with powerful detection capabilities upon which to make precise and personalized drug choices. Although the BRCA1 somatic mutation of patient 1 was not detected, the BRCA1 germline mutation was considered as a high risk for developing malignancy. Thus, drugs such as rucaparib, niraparib, and olaparib could be used for these patients.
Conclusion
This study demonstrated that genetic profiling of cfDNA and CTCs together using our bespoke cancer panel covering 51 actionable genes provides enriched genomic profiling of gynecologic cancers.
In addition, candidate drugs associated with pathogenic alterations were identified using in silico methods. Our study suggests that genetic variant profiling analysis of cfDNA and CTCs combined offers an enriched data set for guiding preclinical and clinical strategies and targeted therapies.
